Protagen Protein Services’ recently acquired Brucker Tensor II IR spectrometer significantly expands the company’s analytical capabilities.
Protagen Protein Services’ (PPS) recently acquired Brucker Tensor II IR spectrometer, which uses Fourier-Transform infrared (FT–IR) spectroscopy technology, significantly enhances the company’s analytical capabilities. The company acquired the new spectrometer in August 2019. Equipped with an AquaSpec transmission cell, the advanced instrument completes and refines the company’s characterization service package by enabling higher order structural characterization as well as providing elaborate results in a relatively short time period.
FT–IR spectroscopy is highly sensitive to the secondary structure of proteins and has been widely used to investigate protein folding. A protein’s secondary structure features-such as alpha helices, beta sheets, and other conformations-are critical parameters that must be assessed diligently.
Comprehensive information on the numerous structural attributes of a protein therapeutic is vital for understanding a protein’s functionality, stability, and antigenicity. FT–IR spectrometers are powerful tools for characterizing the advanced structure of protein-based biologics. They also allow for the monitoring of vibrational modes of the amide bonds within a protein while in its native state and formulation matrix.
While a protein will display many infrared-absorbing bands, amide band I is quite sensitive and representative of the protein conformational states. It is thus used to discern the relative amounts of different types of secondary structure. Together with circular dichroism, FT–IR is part of a comprehensive platform in the characterization of a biologic's secondary structure profile.
The Brucker Tensor II IR spectrometer can conduct rapid and sensitive assays with a high degree of throughput and allows for accelerated data acquisition while at the same time requiring low sample amounts. The transmission cell is specially designed to analyze proteins in aqueous solution. The spectrometer’s FT–IR capability can also be used to analyze buffer components (salts, detergents, excipients). While other stability indicating methods such as differential scanning calorimetry, dynamic light scattering, or hydrogen deuterium exchange–mass spectrometry remain substantial for any protein research object’s analysis, this new platform expands PPS’ range of services and completes overall biopharmaceutical characterization, stability and comparability studies, biosimilarity assessment, and formulation development.
Source: Protagen Protein Services
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.